Does OLAPARIB Cause Recurrent cancer? 77 Reports in FDA Database
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 77 reports of Recurrent cancer have been filed in association with OLAPARIB (Lynparza). This represents 0.4% of all adverse event reports for OLAPARIB.
77
Reports of Recurrent cancer with OLAPARIB
0.4%
of all OLAPARIB reports
3
Deaths
8
Hospitalizations
How Dangerous Is Recurrent cancer From OLAPARIB?
Of the 77 reports, 3 (3.9%) resulted in death, 8 (10.4%) required hospitalization, and 2 (2.6%) were considered life-threatening.
Is Recurrent cancer Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for OLAPARIB. However, 77 reports have been filed with the FAERS database.
What Other Side Effects Does OLAPARIB Cause?
Death (4,378)
Malignant neoplasm progression (1,862)
Nausea (1,582)
Anaemia (1,455)
Fatigue (1,437)
Off label use (777)
Vomiting (642)
Drug ineffective (563)
Diarrhoea (514)
Asthenia (491)
What Other Drugs Cause Recurrent cancer?
NIRAPARIB (776)
IMATINIB (237)
CYCLOPHOSPHAMIDE (143)
TRASTUZUMAB (121)
CAPECITABINE (108)
PEMBROLIZUMAB (107)
RITUXIMAB (99)
DOXORUBICIN (97)
OCTREOTIDE (95)
METHOTREXATE (81)
Which OLAPARIB Alternatives Have Lower Recurrent cancer Risk?
OLAPARIB vs OLARATUMAB
OLAPARIB vs OLECLUMAB
OLAPARIB vs OLIVE OIL\SOYBEAN OIL
OLAPARIB vs OLMESARTAN
OLAPARIB vs OLMESARTAN MEDOXOMIL